Photo by nci from unsplash
17 Introduction Children treated with a cord blood transplant for demyelinating diseases suffer symptom progression until the transplant donor cells engraft in the brain. The cell product DUOC-01 was developed… Click to show full abstract
17 Introduction Children treated with a cord blood transplant for demyelinating diseases suffer symptom progression until the transplant donor cells engraft in the brain. The cell product DUOC-01 was developed as an intrathecal bridging therapy to accelerate delivery of cells to the brain and is currently being studied in a clinical trial in pediatric patients with inherited leukodystrophies under Investigational New Drug number 15338. DUOC-01 is a microglia-like cell product derived from cord blood CD14 monocytes that has been shown to induce remyelination in a mouse model of demyelination.
Journal Title: STEM CELLS Translational Medicine
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!